|
Morphosys Ag (NASDAQ: MOR) |
|
Morphosys Ag
MOR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Morphosys Ag's sales fell
by -14.37 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2151
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Morphosys Ag net loss increased from $-169 millions, to $-213 millions in IV. Quarter 2023,
• More on MOR's Growth
|
|
Morphosys Ag realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.44 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.44.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.4.
• More on MOR's Valuation
|
|
|
|
|
Morphosys Ag realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.44 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.44.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.4.
Morphosys Ag Price to Book Ratio is at 11.84 lower than Industry Avg. of 87.76. and higher than S&P 500 Avg. of 0.02
• More on MOR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com